RecruitingPhase 2Phase 3NCT07204457

Immunogenicity and Safety of Meningococcal Conjugate Vaccine (EG-MCV4) in Healthy Adults Aged 19 to 55 Years Old

Multicenter, Randomized, Subject/Evaluator Blind, Active Control, Phase II/III Clinical Trial to Assess Immunogenicity and Safety of EG-MCV4 Meningococcal (Groups A, C, W-135, and Y) Conjugated Vaccines

Sponsor

EyeGene Inc.

Enrollment

1,123 participants

Start Date

Oct 15, 2025

Study Type

INTERVENTIONAL

Conditions

Meningococcal Infections

Summary

Phase 2/3 study to evaluate immunogenicity and safety in healthy adult participants following a single dose administration of Meningococcal (groups A, C, W-135, and Y) conjugate vaccine

Eligibility

Min Age: 19 YearsMax Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called EG-MCV4 and a biological treatment called Menveo for people with meningococcal infections. The study is currently recruiting participants at 1 location. People eligible for this study include aged 19 Years to 55 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALEG-MCV4

single intramuscular dose on Day 0

BIOLOGICALMenveo

single intramuscular dose on Day 0

Locations(1)

The Catholic University of Eunpyeong St.Mary's Hospital

Seoul, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07204457

Related Trials

Azithromycin for Meningococcal Carriage

NCT066185341 location

Safety and Immunogenicity Following Meningococcal and Pneumococcal Immunization Among Adult People Living With HIV

NCT048758191 location